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Editorial
Breast Cancer Metastasis (MBC) is an ultimate death sentence 
remains a challenge for clinicians worldwide.According to the 
Metastatic Breast Cancer (MBC) Awareness Network about 155,000 
patients are living nowadays with MBC, and about 40,000 deaths are 
reported annually in the United States of America. About 10% of the 
patients visiting the clinic or appearing at the emergency sittings are 
diagnosed with stage IV breast cancer at the initial screening and 
require an urgent and effective treatment, which mainly focuses on 
controlling the disease and improve the quality of life. A breakthrough 
in the clinical trials for the treatment of breast cancer metastasis has 
been observed recently, most of these treatments are mainly drug 
therapies. 
Recently, Palbociclib (Ibrance®) has breakthrough media and 
newspapers as an effective, novel and exciting drug that have received 
in Feb 2015 a granted accelerated approval by the FDA to be used in the 
clinical sittings in combination with Letrozole (Femara®) for patients 
with advanced Metastatic Breast Cancer (MBC). The drug has shown 
well tolerance with slight neutropenia. Palbociclib (Ibrance®) is a potent 
drug acts by selectively inhibiting CDK4 and 6. It prolongs and doubles 
the progression-free survival rate for patients with ER-positive/ HER2-
negative MBC from 10.2 to 20.2 months as shown in several clinical 
trials on about 165 post-menstrual women when combined with 
Letrozole (Femara®) with no prior systemic therapy. Other studies have 
shown the possibility to be used also as a synergistic drug with both 
Transtuzumab (Herceptin®) (Herceptin®) and Tamoxifen (Nolvadex®) 
in patients with ER/HER2 positive MBC. Other CDK4, 6 inhibitors 
such as LY2835210 and LEE001 are also taking place in the clinical 
trials, however their development is still slow. Palbociclib (Ibrance®) 
trials were not limited to MBC, but have also been tested in leukemia, 
brain tumors and mantle cell lymphoma. 
A multicenter study has described the effectiveness of using 
Eribulin Mesylate (Halaven®) in patients with Metastatic Breast Cancer 
(MBC) who had been heavily treated with chemotherapy; the study has 
proven the effectiveness of the drug with a clinical benefit at 6 months 
in approximately 40% of the total enrolled patients. This drug has also 
shown significant efficacy in brain metastasis. Eribulin is a microtubule 
dynamic inhibitor that has also shown significant effect on the Triple 
Negative Breast Cancer cells as well, a recent research has studied its 
mechanism of action and found that it decreases the expression of 
mesenchymal genes while increasing the epithelial markers, therefore 
it mainly works by reversing EMT and inhibiting Smad2 and Smad3 
phosphorylation.
SYD985 is a novel antibody-drug conjugate based on Transtuzumab 
and (vc-seco-DUBA), this drug has significantly address the medical 
need for patient diagnosed with HER2 1+/2+ Metastatic Breast Cancer 
(MBC) including triple negative, and may include in the future as well 
FISH-negative/IHC-HER2 1+/2+ with no effective current medical 
treatment. The results have shown similar potency and activity of 
both drugs in cell lines expressing HER2 3+; however, SYD985 exhibit 
higher potency and activity against HER2 2+/1+ than T-DM1. SYD985 
showed potent anti-tumor activity against FISH-negative cells with 
HER2 1+ or 2+, while T-DM1 did not show activity; this study indicates 
superior anti-tumor activity better than T-DM1.
Accordingly, significant and remarkable success have been made 
to treat Metastatic Breast Cancer (MBC), the above-mentioned drugs 
have delivered hope for those patients and enhanced the progression 
free-survival rate dramatically. Many novel therapies are also under 
clinical trial phases to improve the care and enhance the outcomes of 
Breast Cancer Metastasis.
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